drugset / Trial / NCT06183216
A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine
RandomizedParallel-groupQuadruple-blindPrevention
Summary
A phase 1b clinical trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) developed by Sinovac Life Science Co., Ltd will be conducted in children aged 2 months (42-89 days) and 2 to 5 years. The objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV13. The trial is a randomized, double blinded, positive controlled study.
Timeline
- Start
- 2024-01-04
- Primary completion
- 2025-03-26
- Completion
- 2025-03-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Prevnar 13 | Vaccine | 0.5 ml | Intramuscular |
| Subject | Sinovac PCV13 | Vaccine | 0.5 ml | Intramuscular |